CareLit Fachartikel

Botulinum toxin (BoNT) in headache disorders

S. Silberstein · Aktuelle Neurologie · 2011 · Heft 04

Dokument
1016471
CareLit-ID
Jahr
2011
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Aktuelle Neurologie
Autor:innen
S. Silberstein
Ausgabe
Heft 04 / 2011
Seiten
–
Erschienen: 2011-04-11 00:00:00
ISSN
0302-4350
DOI
10.1055/s-0031-1276544

Zusammenfassung

Headache disorders, including migraine and chronic migraine (headaches ≥15 days/month and a link to migraine) are common debilitating conditions that profoundly impact quality of life. There are 7 BoNT serotypes (A, B, C1, D, E, F, and G). Botulinum toxin type A (BoNTA) has been the most widely studied serotype for therapeutic purposes. Several randomized, double-blind, placebo-controlled studies support the efficacy of BoNT for the treatment of chronic migraine. More recently, the PREEMPT clinical program confirmed OnabotulinumtoxinA as an effective, safe, and well-tolerated headache prophylactic treatment for…

Schlagworte

Migraine Headache Chronic Treatment Therapeutic Efficacy Program Onabotulinumtoxina Further Botulinum Toxin Disorders Aktuelle Neurologie